Coronavirus company news summary – Brazil approves two Covid-19 vaccines, one by SinoVac, the second by AstraZeneca/Oxford – AstraZeneca/Oxford vaccine emergency approved in Nepal

18 January 2021 (Last Updated January 18th, 2021 09:07)

18 January 2020

Dr Reddy’s Laboratories has been granted permission by the Drugs Control General of India to conduct a Phase III clinical trial for Russia’s Sputnik V vaccine in India. The trial is expected to be conducted in India in 1,500 participants and will be a randomised, double-blind, parallel-group, placebo-controlled study.

The Collegiate Board of Anvisa, the Brazilian healthcare regulator, has unanimously approved the use of Sinovac’s CoronaVac vaccine, which was developed in partnership with the Brazilian Butantan Institute, as well as the Covishield vaccine, developed by AstraZeneca/University of Oxford/Fiocruz and produced by the Serum Institute of India. The temporary and exceptional authorisation aims at reducing the impact of the pandemic in Brazil.

Jubilant Therapeutics announced a collaboration with The Wistar Institute to evaluate Peptidyl Arginine Deiminase 4 (PAD4) inhibitors in blocking neutrophil extracellular trap (NET) formation in Covid-19-related cytokine storms. Cytokine storms occur in acute respiratory distress syndrome, a leading cause of death in severely infected Covid-19 patients.

Nepal’s department of drug administration (DDA) granted emergency use for AstraZeneca/University of Oxford’s India-made Covishield vaccine against the Covid-19 disease that has killed 1,950 people across the country. AstraZeneca has partnered with Serum Institute of India, to supply the vaccine to India and other low and middle-income countries.